TrialAnnals of the rheumatic diseases2020

Subcutaneous tanezumab for osteoarthritis of the hip or knee: efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period.

Francis Berenbaum et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.